Feline immunodeficiency virus latency

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  McDonnel, Samantha J ^a,b   Sparger, Ellen E ^b   Murphy, Brian G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal model; Antilatency therapy; Feline; FIV; HIV 1; Latency; Reservoir

Indexed keywords

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FELINE IMMUNODEFICIENCY VIRUS; FELINE IMMUNODEFICIENCY VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MACROPHAGE; NONHUMAN; RETROVIRUS INFECTION; REVIEW; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALS; CATS; DISEASE MODELS, ANIMAL; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; VIRUS LATENCY;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879815146     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-69     Document Type: Review

References (116)

1. Global Fact Sheet. http://www.UNAIDS.org.
2. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010, 5:298-304. 10.1097/COH.0b013e32833a6c32, 3501989, 20543604.
3. Este JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010, 85:25-33. 10.1016/j.antiviral.2009.10.007, 20018390.
4. Kallings LO. The first postmodern pandemic: 25 years of HIV/ AIDS. J Intern Med 2008, 263:218-243. 10.1111/j.1365-2796.2007.01910.x, 18205765.
5. Keedy KS, Margolis DM. Therapy for persistent HIV. Trends Pharmacol Sci 2010, 31:206-211. 10.1016/j.tips.2010.02.001, 2862871, 20207023.
6. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010, 24:2803-2808. 10.1097/QAD.0b013e328340a239, 3154092, 20962613.
7. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180. 10.1126/science.1191047, 20616270.
8. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, Hirschel B, Weber R, Trkola A, Gunthard HF. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008, 105:16725-16730. 10.1073/pnas.0804192105, 2575487, 18936487.
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15:893-900. 10.1038/nm.1972, 2859814, 19543283.
10. Murphy B, Vapniarsky N, Hillman C, Castillo D, McDonnel S, Moore P, Luciw PA, Sparger EE. FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology 2012, 9:12. 10.1186/1742-4690-9-12, 3292463, 22314004.
11. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307. 10.1126/science.1165706, 19265012.
12. Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, Siliciano RF, Zink MC, Clements JE. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009, 83:9247-9257. 10.1128/JVI.00840-09, 2738256, 19570871.
13. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012, 26:1261-1268. 10.1097/QAD.0b013e328353f3f1, 22472858.
14. Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012, 9:5-15. 10.1007/s11904-011-0108-2, 22249405.
15. Yin H, Zhang Y, Zhou X, Zhu H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2010, 38(8):5071-5078.
16. Kim KC, Kim HG, Roh TY, Park J, Jung KM, Lee JS, Choi SY, Kim SS, Choi BS. The effect of CD4 receptor downregulation and its downstream signaling molecules on HIV-1 latency. Biochem Biophys Res Commun 2011, 404:646-651. 10.1016/j.bbrc.2010.12.032, 21146497.
17. Yamagishi M, Ishida T, Miyake A, Cooper DA, Kelleher AD, Suzuki K, Watanabe T. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect 2009, 11:500-508. 10.1016/j.micinf.2009.02.003, 19233310.
18. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007, 39:63-74. 10.1016/j.cyto.2007.05.017, 2063506, 17643313.
19. Ikeda T, Shibata J, Yoshimura K, Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis 2007, 195:716-725. 10.1086/510915, 17262715.
20. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010, 7:37-43. 10.1007/s11904-009-0033-9, 20425056.
21. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009, 6:111. 10.1186/1742-4690-6-111, 2797771, 19961595.
22. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008, 4:123-133. 10.1016/j.chom.2008.05.016, 18692772.
23. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology 2011, 411:344-354. 10.1016/j.virol.2010.12.041, 3618966, 21284992.
24. Tyagi M, Romerio F. Models of HIV-1 persistence in the CD4+ T cell compartment: past, present and future. Curr HIV Res 2011, 9:579-587. 10.2174/157016211798998754, 22211662.
25. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 2012, 7:e30176. 10.1371/journal.pone.0030176, 3265466, 22291913.
26. Duyne RV, Narayanan A, K-Hall K, Saifuddin M, Shultz L, Kashanchi F. Humanized mouse models of HIV-1 latency. Curr HIV Res 2011, 9:595-605. 10.2174/157016211798998781, 22211664.
27. Clements JE, Gama L, Graham DR, Mankowski JL, Zink MC. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS 2011, 6:37-42. 10.1097/COH.0b013e3283412413, 3215305, 21242892.
28. Wongsrikeao P, Saenz D, Rinkoski T, Otoi T, Poeschla E. Antiviral restriction factor transgenesis in the domestic cat. Nat Methods 2011, 8:853-859. 10.1038/nmeth.1703, 21909101.
29. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235:790-793. 10.1126/science.3643650, 3643650.
30. Hayward JJ, Rodrigo AG. Molecular epidemiology of feline immunodeficiency virus in the domestic cat (Felis catus). Vet Immunol Immunopathol 2010, 134:68-74. 10.1016/j.vetimm.2009.10.011, 2821968, 19896220.
31. Kanzaki LI, Looney DJ. Feline immunodeficiency virus: a concise review. Front Biosci 2004, 9:370-377. 10.2741/1235, 14766374.
32. Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 2003, 1:15-29. 10.2174/1570162033352101, 15043209.
33. Elder JH, Lin YC, Fink E, Grant CK. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res 2010, 8:73-80. 10.2174/157016210790416389, 2853889, 20210782.
34. Sparger EE. FIV as a Model for HIV: An Overview 2006, New York: Springer.
35. Hartmann K. Clinical aspects of feline retroviruses: a review. Viruses 2012, 4:2684-2710. 10.3390/v4112684, 3509668, 23202500.
36. Yamamoto JK, Sparger E, Ho EW, Andersen PR, O'Connor TP, Mandell CP, Lowenstine L, Munn R, Pedersen NC. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 1988, 49:1246-1258.
37. Kohmoto M, Uetsuka K, Ikeda Y, Inoshima Y, Shimojima M, Sato E, Inada G, Toyosaki T, Miyazawa T, Doi K, Mikami T. Eight-year observation and comparative study of specific pathogen-free cats experimentally infected with feline immunodeficiency virus (FIV) subtypes A and B: terminal acquired immunodeficiency syndrome in a cat infected with FIV petaluma strain. J Vet Med Sci 1998, 60:315-321. 10.1292/jvms.60.315, 9560779.
38. Ackley CD, Yamamoto JK, Levy N, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 1990, 64:5652-5655. 248623, 1976826.
39. Barlough JE, Ackley CD, George JW, Levy N, Acevedo R, Moore PF, Rideout BA, Cooper MD, Pedersen NC. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr 1991, 4:219-227.
40. Gemeniano MC, Sawai ET, Leutenegger CM, Sparger EE. Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity. J Virol 2003, 77:8819-8830. 10.1128/JVI.77.16.8819-8830.2003, 167212, 12885901.
41. Gemeniano MC, Sawai ET, Sparger EE. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 2004, 325:167-174. 10.1016/j.virol.2004.05.007, 15246256.
42. Chatterji U, de Parseval A, Elder JH. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J Virol 2002, 76:9624-9634. 10.1128/JVI.76.19.9624-9634.2002, 136529, 12208941.
43. Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol 1996, 70:5165-5169. 190471, 8764024.
44. Gulzar N, Copeland KF. CD8+ T-cells: function and response to HIV infection. Curr HIV Res 2004, 2:23-37. 10.2174/1570162043485077, 15053338.
45. Embretson J, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A, Haase AT. Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci U S A 1993, 90:357-361. 10.1073/pnas.90.1.357, 45659, 8419941.
46. English RV, Johnson CM, Gebhard DH, Tompkins MB. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993, 67:5175-5186. 237915, 7688819.
47. Fritsch L, Marechal V, Schneider V, Barthet C, Rozenbaum W, Moisan-Coppey M, Coppey J, Nicolas JC. Production of HIV-1 by human B cells infected in vitro: characterization of an EBV genome-negative B cell line chronically synthetizing a low level of HIV-1 after infection. Virology 1998, 244:542-551. 10.1006/viro.1998.9120, 9601522.
48. Dow SW, Mathiason CK, Hoover EA. In vivo monocyte tropism of pathogenic feline immunodeficiency viruses. J Virol 1999, 73:6852-6861. 112770, 10400783.
49. Dean GA, Himathongkham S, Sparger EE. Differential cell tropism of feline immunodeficiency virus molecular clones in vivo. J Virol 1999, 73:2596-2603. 104014, 10074104.
50. Willett BJ, McMonagle EL, Ridha S, Hosie MJ. Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol 2006, 80:3386-3394. 10.1128/JVI.80.7.3386-3394.2006, 1440405, 16537606.
51. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, Akashi H, Takeuchi Y, Hosie MJ, Willett BJ. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004, 303:1192-1195. 10.1126/science.1092124, 14976315.
52. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC. Epitopes of the CD4 antigen and HIV infection. Science 1986, 234:1120-1123. 10.1126/science.2430333, 2430333.
53. de Parseval A, Chatterji U, Sun P, Elder JH. Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci U S A 2004, 101:13044-13049. 10.1073/pnas.0404006101, 516514, 15326292.
54. Gorry PR, Ancuta P. Coreceptors and HIV-1 pathogenesis. Curr HIV/AIDS Rep 2011, 8:45-53. 10.1007/s11904-010-0069-x, 21188555.
55. Poeschla EM, Looney DJ. CXCR4 is required by a nonprimate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells. J Virol 1998, 72:6858-6866. 109895, 9658135.
56. Broder CC, Collman RG. Chemokine receptors and HIV. J Leukoc Biol 1997, 62:20-29.
57. Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 1999, 73:2576-2586. 104012, 10074102.
58. Yamamoto JK, Sanou MP, Abbott JR, Coleman JK. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res 2010, 8:14-25. 10.2174/157016210790416361, 20210778.
59. Goto Y, Nishimura Y, Baba K, Mizuno T, Endo Y, Masuda K, Ohno K, Tsujimoto H. Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. J Virol 2002, 76:10079-10083. 10.1128/JVI.76.19.10079-10083.2002, 136479, 12208990.
60. Diehl LJ, Mathiason-DuBard CK, O'Neil LL, Hoover EA. Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR. J Virol 1995, 69:2328-2332. 188904, 7533856.
61. Diehl LJ, Mathiason-Dubard CK, O'Neil LL, Obert LA, Hoover EA. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J Virol 1995, 69:6149-6157. 189512, 7666517.
62. Diehl LJ, Mathiason-Dubard CK, O'Neil LL, Hoover EA. Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection. J Virol 1996, 70:2503-2507. 190095, 8642679.
63. Miller MM, Fogle JE. Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection. Viruses 2012, 4:954-962. 10.3390/v4060954, 3397356, 22816034.
64. Miller C, Bielefeldt-Ohmann H, MacMillan M, Huitron-Resendiz S, Henriksen S, Elder J, VandeWoude S. Strain-specific viral distribution and neuropathology of feline immunodeficiency virus. Vet Immunol Immunopathol 2011, 143:282-291. 10.1016/j.vetimm.2011.06.006, 3167954, 21715019.
65. Freer G, Matteucci D, Mazzetti P, Tarabella F, Ricci E, Bozzacco L, Merico A, Pistello M, Ceccherini-Nelli L, Bendinelli M. Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course. Retrovirology 2008, 5:33. 10.1186/1742-4690-5-33, 2373306, 18416857.
66. Kraase M, Sloan R, Klein D, Logan N, McMonagle L, Biek R, Willett BJ, Hosie MJ. Feline immunodeficiency virus env gene evolution in experimentally infected cats. Vet Immunol Immunopathol 2010, 134:96-106. 10.1016/j.vetimm.2009.10.015, 19897254.
67. Giannecchini S, Pistello M, Isola P, Matteucci D, Mazzetti P, Freer G, Bendinelli M. Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus. J Virol 2007, 81:10474-10485. 10.1128/JVI.01064-07, 2045460, 17634241.
68. Pistello M, Matteucci D, Cammarota G, Mazzetti P, Giannecchini S, Del Mauro D, Macchi S, Zaccaro L, Bendinelli M. Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. J Virol 1999, 73:1518-1527. 103976, 9882357.
69. English RV, Nelson P, Johnson CM, Nasisse M, Tompkins WA, Tompkins MB. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus. J Infect Dis 1994, 170:543-552. 10.1093/infdis/170.3.543, 8077711.
70. Hofmann-Lehmann R, Holznagel E, Ossent P, Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin Diagn Lab Immunol 1997, 4:33-42. 170472, 9008278.
71. Callanan JJ, Racz P, Thompson H, Jarrett O. Lymph node pathology in experimental FIV infection. Adv Exp Med Biol 1994, 355:169-175.
72. Poli A, Abramo F, Di Iorio C, Cantile C, Carli MA, Pollera C, Vago L, Tosoni A, Costanzi G. Neuropathology in cats experimentally infected with feline immunodeficiency virus: a morphological, immunocytochemical and morphometric study. J Neurovirol 1997, 3:361-368. 10.3109/13550289709030750, 9372457.
73. Poli A, Tozon N, Guidi G, Pistello M. Renal alterations in feline immunodeficiency virus (FIV)-infected cats: a natural model of lentivirus-induced renal disease changes. Viruses 2012, 4:1372-1389. 10.3390/v4091372, 3499810, 23170163.
74. Mandell C, Sparger EE, Pedersen NC, Jain NC. Long-term haematological changes in cats experimentally infected with feline immunodeficiency virus (FIV). Comp Haematol Int 1992, 2:8-17.
75. Torten M, Franchini M, Barlough JE, George JW, Mozes E, Lutz H, Pedersen NC. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol 1991, 65:2225-2230. 240570, 1673159.
76. Lehmann R, von Beust B, Niederer E, Condrau MA, Fierz W, Aubert A, Ackley CD, Cooper MD, Tompkins MB, Lutz H. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Vet Immunol Immunopathol 1992, 35:199-214. 10.1016/0165-2427(92)90132-A, 1363009.
77. Tompkins MB, Tompkins WA. Lentivirus-induced immune dysregulation. Vet Immunol Immunopathol 2008, 123:45-55. 10.1016/j.vetimm.2008.01.011, 2410212, 18289702.
78. Vahlenkamp TW, Tompkins MB, Tompkins WA. Feline immunodeficiency virus infection phenotypically and functionally activates immunosuppressive CD4 + CD25+ T regulatory cells. J Immunol 2004, 172:4752-4761.
79. Beatty JA, Willett BJ, Gault EA, Jarrett O. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol 1996, 70:6199-6206. 190644, 8709246.
80. Joshi A, Vahlenkamp TW, Garg H, Tompkins WA, Tompkins MB. Preferential replication of FIV in activated CD4(+)CD25(+)T cells independent of cellular proliferation. Virology 2004, 321:307-322. 10.1016/j.virol.2004.01.014, 15051390.
81. Joshi A, Garg H, Tompkins MB, Tompkins WA. Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors. J Virol 2005, 79:4965-4976. 10.1128/JVI.79.8.4965-4976.2005, 1069539, 15795282.
82. Lankford S, Petty C, LaVoy A, Reckling S, Tompkins W, Dean GA. Cloning of feline FOXP3 and detection of expression in CD4 + CD25+ regulatory T cells. Vet Immunol Immunopathol 2008, 122:159-166. 10.1016/j.vetimm.2007.11.007, 2277518, 18180044.
83. Smithberg SR, Fogle JE, Mexas AM, Reckling SK, Lankford SM, Tompkins MB, Dean GA. In vivo depletion of CD4 + CD25+ regulatory T cells in cats. J Immunol Methods 2008, 329:81-91. 10.1016/j.jim.2007.09.015, 2246310, 17980384.
84. Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 2009, 29:187-201. 10.1615/CritRevImmunol.v29.i3.10, 3180959, 19538134.
85. Joshi A, Garg H, Tompkins MB, Tompkins WA. Different thresholds of T cell activation regulate FIV infection of CD4 + CD25+ and CD4 + CD25- cells. Virology 2005, 335:212-221. 10.1016/j.virol.2005.02.016, 15840520.
86. Mikkelsen SR, Reckling SK, Egan EA, Dean GA. In vivo depletion of CD4(+)CD25(hi) regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus. Virology 2010, 403:163-172. 10.1016/j.virol.2010.04.016, 2879469, 20471053.
87. Ikeda Y, Tomonaga K, Kawaguchi Y, Kohmoto M, Inoshima Y, Tohya Y, Miyazawa T, Kai C, Mikami T. Feline immunodeficiency virus can infect a human cell line (MOLT-4) but establishes a state of latency in the cells. J Gen Virol 1996, 77(Pt 8):1623-1630.
88. Tochikura TS, Naito Y, Kozutsumi Y, Hohdatsu T. Induction of feline immunodeficiency virus from a chronically infected feline T-lymphocyte cell line. Res Vet Sci 2012, 92:327-332. 10.1016/j.rvsc.2011.02.013, 21477828.
89. Assogba BD, Leavell S, Porter K, Burkhard MJ. Mucosal administration of low-dose cell-associated feline immunodeficiency virus promotes viral latency. J Infect Dis 2007, 195:1184-1188. 10.1086/512861, 17357056.
90. Tomonaga K, Inoshima Y, Ikeda Y, Mikami T. Temporal patterns of feline immunodeficiency virus transcripts in peripheral blood cells during the latent stage of infection. J Gen Virol 1995, 76(Pt 9):2193-2204.
91. McDonnel SJ, Sparger EE, Luciw PA, Murphy BG. Transcriptional Regulation of Latent Feline Immunodeficiency Virus in Peripheral CD4+ T-lymphocytes. Viruses 2012, 4:878-888. 10.3390/v4050878, 3386631, 22754653.
92. Lin X, Irwin D, Kanazawa S, Huang L, Romeo J, Yen TS, Peterlin BM. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol 2003, 77:8227-8236. 10.1128/JVI.77.15.8227-8236.2003, 165222, 12857891.
93. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188. 10.1038/387183a0, 9144289.
94. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H, et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A 2011, 108:11199-11204. 10.1073/pnas.1107729108, 3131354, 21690402.
95. Uckun FM, Chen CL, Samuel P, Pendergrass S, Venkatachalam TK, Waurzyniak B, Qazi S. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 2003, 47:1233-1240. 10.1128/AAC.47.4.1233-1240.2003, 152500, 12654652.
96. Alix C, Martin JP, Braunwald J. Temperature sensitivity of two different steps in the viral life cycle of feline immunodeficiency virus. Virology 1999, 253:309-318. 10.1006/viro.1998.9506, 9918889.
97. Murphy B, Hillman C, Mok M, Vapniarsky N. Lentiviral latency in peripheral CD4+ T cells isolated from feline immunodeficiency virus-infected cats during the asymptomatic phase is not associated with hypermethylation of the proviral promoter. Virus Res 2012, 169:117-126. 10.1016/j.virusres.2012.07.017, 22846918.
98. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009, 5:e1000554. 10.1371/journal.ppat.1000554, 2722084, 19696893.
99. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009, 5:e1000495. 10.1371/journal.ppat.1000495, 2695767, 19557157.
100. Blazkova J, Murray D, Justement JS, Funk EK, Nelson AK, Moir S, Chun TW, Fauci AS. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol 2012, 86:5390-5392. 10.1128/JVI.00040-12, 3347337, 22345448.
101. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 2011, 6:25-29. 10.1097/COH.0b013e328341242d, 3079555, 21242890.
102. Taube R, Peterlin M. Lost in transcription: molecular mechanisms that control HIV latency. Viruses 2013, 5:902-927. 10.3390/v5030902, 3705304, 23518577.
103. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002, 53:557-593. 10.1146/annurev.med.53.082901.104024, 11818490.
104. McDonnel SJ, Sparger EE, Luciw PA, Murphy BG. Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Res 2012, 170:174-179. 10.1016/j.virusres.2012.10.009, 23073179.
105. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012, 90:47-54. 10.1038/icb.2011.95, 22083528.
106. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011, 286:22211-22218. 10.1074/jbc.M110.180224, 3121366, 21531716.
107. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009, 284:6782-6789. 2652322, 19136668.
108. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009, 25:207-212. 10.1089/aid.2008.0191, 2853863, 19239360.
109. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108. 10.1097/00002030-200405210-00003, 15166525.
110. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485. 10.1038/nature11286, 3704185, 22837004.
111. Chan CN, McMonagle EL, Hosie MJ, Willett BJ. Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4(+) T-cells. Virus Res 2013, 171:121-128. 10.1016/j.virusres.2012.11.004, 3566544, 23201205.
112. Sanchez-Duffhues G, Vo MQ, Perez M, Calzado MA, Moreno S, Appendino G, Munoz E. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets 2011, 12:348-356. 10.2174/138945011794815266, 20955147.
113. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009, 4:e6093. 10.1371/journal.pone.0006093, 2699633, 19564922.
114. Hezareh M. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 2005, 18:496-500. 10.1358/dnp.2005.18.8.944543, 16391719.
115. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S, Margolis LB, Hirsch I. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 2004, 78:10507-10515. 10.1128/JVI.78.19.10507-10515.2004, 516376, 15367617.
116. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501. 10.1016/j.immuni.2012.01.014, 3501645, 22406268.